Evidence map›Paper›PMID 41522663›Full record

ArticleJBMR plus2026

Romosozumab after rebound vertebral fractures induced by denosumab discontinuation: a case series.

Marcelo Sarli, Vanina Farias, Rubén Abdala, Estefanía Armanelli, Cintia Bocci, Fernando Jerkovich, María Belén Zanchetta

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marcelo SarliDepartment of Endocrinology, IDIM,  Buenos Aires, C1012AAR, Argentina.
Vanina FariasDepartment of Endocrinology, IDIM,  Buenos Aires, C1012AAR, Argentina.
Rubén AbdalaDepartment of Endocrinology, IDIM,  Buenos Aires, C1012AAR, Argentina.
Estefanía ArmanelliDepartment of Bone and Mineral Metabolism, Facultad de Medicina, Universidad del Salvador, Buenos Aires, C1055AAG, Argentina.
Cintia BocciDepartment of Bone and Mineral Metabolism, Facultad de Medicina, Universidad del Salvador, Buenos Aires, C1055AAG, Argentina.
Fernando JerkovichDepartment of Endocrinology, IDIM,  Buenos Aires, C1012AAR, Argentina.
María Belén ZanchettaDepartment of Endocrinology, IDIM,  Buenos Aires, C1012AAR, Argentina.ORCID https://orcid.org/0000-0002-9397-1847

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDiscontinuation of denosumab can lead to a rebound increase in bone resorption, which may result in multiple vertebral fractures. Current guidelines recommend retreatment with denosumab or administration of zoledronate in this setting. MATERIALS AND

methodsWe report a series of 4 patients who developed vertebral fractures following denosumab withdrawal and were subsequently treated with romosozumab, a dual-action agent with anabolic and antiresorptive properties.

resultsAll patients showed progressive improvement in BMD and microarchitecture, with suppression of bone turnover markers and no new clinical fractures during treatment and follow-up. DISCUSSION: Although limited by the uncontrolled design and small sample size, these observations suggest that romosozumab might be considered as a potential therapeutic approach for selected patients with post-denosumab rebound fractures.

Indexed as

anabolicsantiresorptivesbiochemical markers of bone turnoverbone QCT/micro-CTDXAosteoporosis

Identifiers

PMID41522663
PMCPMC12790271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.